Injectable Testosterone Undecanoate for Deficiency Treatment

According to GlobalData’s company profile on Chong Kun Dang Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Chong Kun Dang Pharmaceutical‘s grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11826460B2) discloses an injectable composition for sustained release containing testosterone undecanoate as the active ingredient. The composition includes sesame oil or safflower oil as the oil component and benzyl benzoate as the solvent. The weight ratios of testosterone undecanoate to benzyl benzoate and oil range from 1:1 to 1:3, with a viscosity of 10 to 110 mPas at 4 to 30°C as per the USP rotational rheometer method.

Moreover, the patent claims specify that the injectable composition should exhibit specific injection force requirements when administered using different needle sizes. Additionally, the composition is designed for administration every 4 to 16 weeks and maintains a high percentage of the active ingredient when stored under acidic conditions. The injectable composition is primarily intended for the prevention or treatment of hypogonadism and is formulated for intramuscular injection, providing a novel approach to sustained testosterone release.

To know more about GlobalData’s detailed insights on Chong Kun Dang Pharmaceutical, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies